The Business in Healthcare Conference is the largest healthcare conference held annually at the Johns Hopkins Carey Business School. The theme of this year’s conference is Precision Medicine with the mission of educating graduate students, alumni, and industry professionals about key developments in precision medicine impacting our healthcare system. In particular, we are forming panels of speakers with experience across the healthcare industry to answer some of today’s most pressing business questions:
- How will the healthcare landscape need to evolve to overcome the barriers in the application of consumer health tech and improve the treatment experience?
- How will the advancement of molecular diagnostics and the availability of patient genetic information impact the payer-provider dynamic?
- How will the development of personalized medicines affect healthcare policy, regulations, and pricing?
In thinking about the intersection between business and healthcare, we hope the conference will serve as a platform for facilitating an engaging discussion and networking opportunities around successful innovation in healthcare.
Healthcare Consumerism & Preventive Care
Key Business Question: How will the healthcare landscape need to evolve to overcome the barriers in consumer health tech and improve the treatment experience?
With the rapid development in precision medicine, patients and caregivers have become more connected and deeply integrated with their care and treatment options than ever before. The rise in consumer health technologies has opened the door to new questions that require deep and meaningful consideration into the impacts these advancements have on healthcare professionals.
Gracelyn McDermott, M.B.A.
Santosh Venkatesha, M.B.A.
Caroline Popper, M.D.
Pothik Chatterjee, M.B.A.
Companion Diagnostics & Biomarkers
Key Business Question: How will the advancement of molecular diagnostics and the availability of patient genetic information impact the payer-provider dynamic?
As the fields of medicine and technology have become more deeply intertwined than ever before, healthcare professionals now have an enhanced capability to diagnose and customize their treatment approaches for patients. Within this evolution in the healthcare field, it is now crucial for researchers, data scientists, and clinicians to collaborate on measuring the clinical outcomes and overall value proposition for diagnostic technologies. This panel will consider both the ethical and clinical implications that arise from the use of such technologies on patients, payers, and providers.
Justin Sacks, M.D., M.B.A.
Edward Bessman, M.D., M.B.A.
Dan Edelstein, M.B.A.
Drug Development & Targeted Therapies
Key Business Question: How will the development of personalized medicines affect healthcare policy, regulations, and pricing?
Scientific advancements in the pharmaceutical and biotech space have resulted in personalized treatments that have the potential to significantly improved the quality of life for patients. Simultaneously, there is significant debate around the healthcare policy and government regulations, as well as the pricing practices, that should accompany the development of such therapies.
Aiman Shalabi, PharmD
Daniel J. Durand, M.D.
Annastasiah Mudiwa Mhaka, PhD
Keynote Speaker: Dr. Kathy McGroddy-Goetz
Kathy McGroddy-Goetz is the Head of Strategic Partnerships at Medidata Solutions. She is responsible for managing strategic collaborations with key industry leaders to transform clinical trials for patients, sites, and sponsors.
Dr. McGroddy-Goetz joined Medidata after a 26-year career at IBM innovating at the intersection of advanced technologies and new business models, with an emphasis on Healthcare and Life Sciences solutions. She spent two years as Director of Corporate Technology, leading IBM’s technology strategy, and has significant expertise in developing innovative medical imaging solutions. She played a critical role in the corporation’s launch of Watson Health, called a “moon shot” by CRO Ginni Rometty and led the Global Strategic Partnerships & Alliances team for Watson Health for three years.
Dr. McGroddy-Goetz earned a BS in physics from SUNY Binghamton and a PhD in molecular biophysics from Cornell University, where she studied protein-ligand interactions using NMR spectroscopy and molecular dynamics simulations. She holds five patents and is a frequent speaker at industry and technology conferences.